Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1999 Sep;67(9):4744-50.
doi: 10.1128/IAI.67.9.4744-4750.1999.

Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype

Affiliations

Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype

R B Parad et al. Infect Immun. 1999 Sep.

Abstract

Whether allelic variants of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) independently contribute to pulmonary outcome in CF patients has not been resolved. We used both cross-sectional and mixed-model longitudinal analyses of data from CF patients that were at least 12 years old to determine the influence on pulmonary function (percent predicted forced expiratory volume [FEV(1)]) of the CFTR gene genotype, gender, mucoid Pseudomonas aeruginosa (MPA) infection status, presence of total opsonic antibody to MPA, and, separately, the opsonic antibody activity specific to the mucoid exopolysaccharide (MEP) surface antigen. Two different factors were independently associated with the lack of MPA infection: a high level of MEP-specific opsonic activity (MSOA), implicating an immunologically based mechanism of resistance to infection, and a lack of any type of opsonic antibody to MPA, indicative of no significant exposure or infection. This latter phenotype was found in a subset of CF patients who carried at least one uncommon CFTR gene allele suggestive of a genetic basis for resistance to infection in this group of older CF patients. For CF patients in whom both CFTR gene alleles were identified by screening for the 12 most common variants (75% of alleles), cross-sectional analysis showed that MPA infection was best correlated with lower percent predicted FEV(1), while genotype (two versus one DeltaF508 CFTR gene allele) and a low level of MSOA were associated with increased risk of infection. A mixed-model analysis of longitudinal spirometric measurements that considered multiple risk factors to derive regression equations was used to determine which clinical parameters had the greatest effect on the annual rate of decline in percent predicted FEV(1). This analysis showed that the CFTR gene genotype only modestly modified the constant (y intercept) of the derived equations, while gender and MPA infection status had the largest effects on annual rates of decline in percent predicted FEV(1). These results indicate that the CFTR genotype is usually not a primary determinant of pulmonary function in most CF patients, but gender and MPA infection status are. Infection status is potentially influenced by both immunologic (a high level of MSOA) and genetic factors, such as carriage of a CFTR gene allele that leads to a diagnosis of CF but still confers resistance to infection that is comparable to that of the wild-type CFTR gene.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Schematic diagram of subject selection.
FIG. 2
FIG. 2
Relationship between the percentage of serum opsonic antibodies to MPA that encompass the MSOA and the estimated probability of MPA infection.
FIG. 3
FIG. 3
Comparison of the slopes for the annual rate of decline in percent predicted FEV1 among CF patients homozygous for the ΔF508 CFTR gene allele that had a titer of opsonic antibody to MPA of ≥5. Bars represent means of slope of annual rate of decline, and error bars indicate the standard errors. IF, infected female; IM, infected male; UF, uninfected female; UM, uninfected male; Δ, difference between means; SE, standard error of difference between means.

References

    1. Borgo G, Gasparini P, Bonizzato A, Cabrini G, Mastella G, Pignatti P F. Cystic fibrosis: the ΔF508 mutation does not lead to an exceptionally severe phenotype. A cohort study. Eur J Pediatr. 1993;152:1006–1011. - PubMed
    1. Campbell P W, III, Parker R A, Roberts B T, Krishnamani M R, Phillips J A., III Association of poor clinical status and heavy exposure to tobacco smoke in patients with cystic fibrosis who are homozygous for the ΔF508 deletion. J Pediatr. 1992;120:261–264. - PubMed
    1. Campbell P W, III, Phillips III J A, Krishnamani M R, Maness K J, Hazinski T A. Cystic fibrosis: relationship between clinical status and ΔF508 deletion. J Pediatr. 1991;118:239–241. - PubMed
    1. Chillon M, Casals T, Mercier B, Bassas L, Lissens W, Silber S, Romey M C, Ruizromero J, Verlingue C, Claustres M, Nunes V, Ferec C, Estivill X. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med. 1995;332:1475–1480. - PubMed
    1. Corey M, Edwards L, Levison H, Knowles M. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr. 1997;131:809–814. - PubMed

Publication types

MeSH terms

Substances